Astrazeneca Pharma India Live BSE/NSE | Astrazeneca Pharma India Fundamenta data | Astrazeneca Pharma India Balance sheet | Astrazeneca Pharma India Quarterly Results | Astrazeneca Pharma India Profit & Loss | Astrazeneca Pharma India Financial Ratios

Stock Summary

Market Cap(Crs)
Stock P:E
Face Value

8,843.88
122.47
2

Enterprise Value(Crs)
Dividend Yield
Price:Book Value

8,670.58
0.03%
24.27

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

10 Years
5 Years
3 Years

-
7.09
10.23

EBITDA CAGR (%)

10 Years
5 Years
3 Years

-
-
14.06

PAT CAGR (%)

10 Years
5 Years
3 Years

-
-
39.52

P:E (Median)

8 Years
5 Years
3 Years

79.94
111.98
105.55

P:BV (Average)

8 Years
5 Years
3 Years

19.93
19.93
19.93

EV:EBITDA (Average)

8 Years
5 Years
3 Years

41.55
66.29
55.92

Quarterly Results

Standalone Figures in Rs. Crores

Description Mar 20 Mar 19 Var% Dec 19 Dec 18 Var% Sep 19 Sep 18 Var% Jun 19 Jun 18 Var%
Net Sales 195 190 2% 224 215 4% 208 161 29% 205 161 27%
Expenses 180 184 -2% 187 174 7% 175 147 19% 169 152 11%
EBITDA 15 6 132% 37 41 -10% 34 15 127% 36 9 283%
EBIDTM 8% 3% 16% 19% 16% 9% 17% 6%
Other Income 3 6 -44% 3 4 -1% 3 3 -6% 3 3 -13%
Interest 0 0 0 0 0 0 0 0 0 0 0 0
Depreciation 5 4 16% 5 4 26% 5 4 26% 5 4 30%
PBT 13 8 58% 35 41 -13% 32 14 120% 34 9 268%
Tax 4 -1 - 8 12 -26% 17 5 227% 12 3 339%
PAT 10 10 -2% 27 29 -8% 14 9 58% 22 6 237%
PATM 5% 5% 12% 14% 7% 6% 11% 4%
EPS 3.83 3.93 -3% 10.68 11.64 -8% 5.77 3.65 58% 8.61 2.56 236%

Description Mar 20 Mar 19 Var% Dec 19 Dec 18 Var% Sep 19 Sep 18 Var% Jun 19 Jun 18 Var%
Net Sales 0 0 0 0 0 0 0 0 0 0 0 0
Expenses 0 0 0 0 0 0 0 0 0 0 0 0
EBITDA 0 0 0 0 0 0 0 0 0 0 0 0
EBIDTM 0% 0% 0% 0% 0% 0% 0% 0%
Other Income 0 0 0 0 0 0 0 0 0 0 0 0
Interest 0 0 0 0 0 0 0 0 0 0 0 0
Depreciation 0 0 0 0 0 0 0 0 0 0 0 0
PBT 0 0 0 0 0 0 0 0 0 0 0 0
Tax 0 0 0 0 0 0 0 0 0 0 0 0
PAT 0 0 0 0 0 0 0 0 0 0 0 0
PATM 0% 0% 0% 0% 0% 0% 0% 0%
EPS 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0

Annual Results

Standalone Figures in Rs. Crores

Description TTM Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14 Mar 13 Mar 12 Mar 11 Dec 09
Net Sales 832 728 571 544 564 517 474 390 531 594 397 Net Sales Growth 14% 28% 5% -4% 9% 9% 21% -26% -11% 50% Cost Of Goods Sold 305 227 178 171 195 194 155 147 162 159 108 Gross Profit 527 502 393 373 369 323 319 244 369 435 289 GP Margin 63% 69% 69% 69% 65% 62% 67% 62% 69% 73% 73% Total Expenditure 711 657 525 507 547 528 487 459 501 490 308 Power & Fuel Cost - 8 8 8 7 9 9 6 3 3 2 % Of Sales - 1% 1% 1% 1% 2% 2% 1% 1% 1% 0% Employee Cost - 197 150 162 169 160 160 148 162 150 81 % Of Sales - 27% 26% 30% 30% 31% 34% 38% 30% 25% 20% Manufacturing Exp. - 50 51 36 26 18 36 38 38 30 27 % Of Sales - 7% 9% 7% 5% 3% 8% 10% 7% 5% 7% General & Admin Exp. - 74 46 55 59 64 67 64 95 89 56 % Of Sales - 10% 8% 10% 10% 12% 14% 16% 18% 15% 14% Selling & Distn. Exp. - 88 81 63 85 78 56 51 34 51 30 % Of Sales - 12% 14% 12% 15% 15% 12% 13% 6% 9% 7% Miscellaneous Exp. - 13 10 12 6 7 5 5 6 7 30 % Of Sales - 2% 2% 2% 1% 1% 1% 1% 1% 1% 1% EBITDA 121 71 46 37 16 -11 -13 -68 30 104 89 EBITDA Margin 15% 10% 8% 7% 3% -2% -3% -18% 6% 17% 22% Other Income 13 16 12 14 7 6 9 10 6 6 6 Interest 1 0 0 0 0 0 0 0 0 0 0 Depreciation 19 15 15 16 17 15 10 12 7 9 6 PBT 114 73 44 36 6 -21 -14 -70 29 101 88 Tax 42 18 18 15 0 0 1 19 9 37 31 Tax Rate 37% 25% 41% 44% 9% 0% 0% -27% 32% 36% 35% PAT 72 54 26 20 5 -21 -1 -90 20 64 58 PAT before Minority Interest 72 54 26 20 5 -21 -1 -90 20 64 58 Minority Interest 0 0 0 0 0 0 0 0 0 0 0 PAT Margin 9% 7% 5% 4% 1% -4% 0% -23% 4% 11% 15% PAT Growth 33% 110% 29% 281% 125% -3,986% 99% -553% -69% 11% EPS 28.89 21.78 10.36 8.02 2.10 -8.34 -0.20 -35.81 7.91 25.65 23.05

Description

TTM

Mar 19

Mar 18

Mar 17

Mar 16

Mar 15

Mar 14

Mar 13

Mar 12

Mar 11

Dec 09

Net Sales

832

728

571

544

564

517

474

390

531

594

397

Net Sales Growth

14%

28%

-4%

21%

-26%

-11%

50%

Cost Of Goods Sold

305

227

178

171

195

194

155

147

162

159

108

Gross Profit

527

502

393

373

369

323

319

244

369

435

289

GP Margin

63%

69%

65%

62%

67%

62%

69%

73%

Total Expenditure

711

657

525

507

547

528

487

459

501

490

308

Power & Fuel Cost

% Of Sales

Employee Cost

197

150

162

169

160

148

162

150

% Of Sales

27%

26%

30%

31%

34%

38%

30%

25%

20%

Manufacturing Exp.

% Of Sales

10%

General & Admin Exp.

% Of Sales

10%

12%

14%

16%

18%

15%

14%

Selling & Distn. Exp.

% Of Sales

12%

14%

12%

15%

12%

13%

Miscellaneous Exp.

% Of Sales

EBITDA

121

-11

-13

-68

104

EBITDA Margin

15%

10%

-2%

-3%

-18%

17%

22%

Other Income

Interest

Depreciation

PBT

114

-21

-14

-70

101

Tax

Tax Rate

37%

25%

41%

44%

-27%

32%

36%

35%

PAT

-21

-1

-90

PAT before Minority Interest

-21

-1

-90

Minority Interest

PAT Margin

-4%

-23%

11%

15%

PAT Growth

33%

110%

29%

281%

125%

-3,986%

99%

-553%

-69%

11%

EPS

28.89

21.78

10.36

8.02

2.10

-8.34

-0.20

-35.81

7.91

25.65

23.05

Results Balance Sheet

Standalone Figures in Rs. Crores

Description Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14 Mar 13 Mar 12 Mar 11 Dec 09
Shareholder's Funds 301 247 223 156 151 172 100 189 180 145 Share Capital 5 5 5 5 5 5 5 5 5 5 Total Reserves 294 240 216 151 146 167 95 184 175 140 Non-Current Liabilities 23 110 89 39 1 0 0 -17 -4 -3 Secured Loans 0 0 0 0 0 0 0 0 0 0 Unsecured Loans 0 0 0 0 0 0 0 0 0 0 Long Term Provisions 46 142 129 38 0 0 0 0 3 0 Current Liabilities 268 219 202 234 260 244 206 155 125 89 Trade Payables 168 127 88 95 111 110 91 21 14 12 Other Current Liabilities 54 39 70 121 112 96 77 67 63 34 Short Term Borrowings 0 0 0 0 0 0 0 0 0 0 Short Term Provisions 45 52 45 18 37 37 38 67 48 43 Total Liabilities 591 575 514 429 412 416 306 327 301 231 Net Block 75 75 87 97 101 94 25 32 27 30 Gross Block 120 106 103 204 191 170 99 95 85 83 Accumulated Depreciation 45 30 16 106 90 76 74 64 57 53 Non Current Assets 178 243 250 162 148 141 141 133 82 30 Capital Work in Progress 7 4 5 6 12 9 74 58 24 0 Non Current Investment 0 0 0 0 0 0 0 0 0 0 Long Term Loans & Adv. 96 163 158 58 35 37 35 40 27 0 Other Non Current Assets 0 0 0 1 1 0 8 2 3 0 Current Assets 413 333 263 267 263 275 165 195 220 201 Current Investments 0 0 0 0 0 0 0 0 0 0 Inventories 118 113 58 77 86 96 85 75 57 35 Sundry Debtors 80 55 43 83 43 53 28 32 44 68 Cash & Bank 173 126 116 77 25 89 18 53 85 68 Other Current Assets 42 10 24 10 109 37 33 34 33 29 Short Term Loans & Adv. 29 28 23 20 107 32 20 23 28 26 Net Current Assets 146 114 61 33 3 31 -41 40 94 111 Total Assets 591 575 514 429 412 416 306 327 301 231

Description

Mar 19

Mar 18

Mar 17

Mar 16

Mar 15

Mar 14

Mar 13

Mar 12

Mar 11

Dec 09

Shareholder's Funds

301

247

223

156

151

172

100

189

180

145

Share Capital

Total Reserves

294

240

216

151

146

167

184

175

140

Non-Current Liabilities

110

-17

-4

-3

Secured Loans

Unsecured Loans

Long Term Provisions

142

129

Current Liabilities

268

219

202

234

260

244

206

155

125

Trade Payables

168

127

111

110

Other Current Liabilities

121

112

Short Term Borrowings

Short Term Provisions

Total Liabilities

591

575

514

429

412

416

306

327

301

231

Net Block

101

Gross Block

120

106

103

204

191

170

Accumulated Depreciation

106

Non Current Assets

178

243

250

162

148

141

133

Capital Work in Progress

Non Current Investment

Long Term Loans & Adv.

163

158

Other Non Current Assets

Current Assets

413

333

263

267

263

275

165

195

220

201

Current Investments

Inventories

118

113

Sundry Debtors

Cash & Bank

173

126

116

Other Current Assets

109

Short Term Loans & Adv.

107

Net Current Assets

146

114

-41

111

Total Assets

591

575

514

429

412

416

306

327

301

231

Cash Flow

Standalone Figures in Rs. Crores

Description Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14 Mar 13 Mar 12 Mar 11 Dec 09
Cash From Operating Activity 55 9 38 57 -46 -1 -6 39 64 33 PBT 73 44 36 6 -21 0 -70 29 101 88 Adjustment 8 3 15 12 9 -11 3 2 3 3 Changes in Working Capital 10 -34 0 42 -33 18 61 39 5 -23 Cash after chg. in Working capital 90 13 50 60 -45 7 -6 70 109 68 Interest Paid 0 0 0 0 0 0 0 0 0 0 Tax Paid -35 -4 -12 -3 -1 -8 0 -31 -45 -36 Other Direct Exp. Paid 0 0 0 0 0 0 0 0 0 0 Extra & Other Items 0 0 0 0 0 0 0 0 0 0 Cash From Investing Activity 4 -9 0 -4 -19 -15 -16 -34 -28 2 Net Fixed Assets -17 -2 103 -6 -25 -7 -18 -45 -25 -2 Net Investments 0 0 0 0 0 0 0 0 0 0 Others 22 -7 -102 3 6 -8 3 12 -2 4 Cash from Financing Activity 0 0 0 -1 0 86 -10 -29 -29 -111 Net Cash Inflow / Outflow 59 -1 38 53 -64 71 -32 -24 8 -76 Opening Cash & Equivalents 114 115 76 23 88 17 49 73 65 144 Closing Cash & Equivalent 173 114 115 76 23 88 17 49 73 68

Description

Mar 19

Mar 18

Mar 17

Mar 16

Mar 15

Mar 14

Mar 13

Mar 12

Mar 11

Dec 09

Cash From Operating Activity

-46

-1

-6

PBT

-21

-70

101

Adjustment

-11

Changes in Working Capital

-34

-33

-23

Cash after chg. in Working capital

-45

-6

109

Interest Paid

Tax Paid

-35

-4

-12

-3

-1

-8

-31

-45

-36

Other Direct Exp. Paid

Extra & Other Items

Cash From Investing Activity

-9

-4

-19

-15

-16

-34

-28

Net Fixed Assets

-17

-2

103

-6

-25

-7

-18

-45

-25

-2

Net Investments

Others

-7

-102

-8

-2

Cash from Financing Activity

-1

-10

-29

-111

Net Cash Inflow / Outflow

-1

-64

-32

-24

-76

Opening Cash & Equivalents

114

115

144

Closing Cash & Equivalent

173

114

115

Financial Ratios

Standalone

Description Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14 Mar 13 Mar 12 Mar 11 Dec 09
Book Value (Rs.) 119 98 88 62 60 69 40 76 72 58 ROA 9% 5% 4% 1% -5% 0% -28% 6% 24% 22% ROE 20% 11% 11% 3% -13% 0% -62% 11% 40% 44% ROCE 27% 19% 19% 4% -13% 0% -49% 16% 62% 55% Fixed Asset Turnover 6.45 5.49 3.58 2.88 2.91 3.61 4.11 6.05 7.24 4.94 Receivable days 34 31 42 40 33 30 28 26 34 53 Inventory Days 58 55 45 52 63 68 74 44 28 31 Payable days 91 73 76 75 86 82 50 15 12 14 Cash Conversion Cycle 0 12 11 17 11 17 51 55 50 71 Total Debt/Equity 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Interest Cover 0 0 0 0 0 0 0 0 0 646

Description

Mar 19

Mar 18

Mar 17

Mar 16

Mar 15

Mar 14

Mar 13

Mar 12

Mar 11

Dec 09

Book Value (Rs.)

119

ROA

-5%

-28%

24%

22%

ROE

20%

11%

-13%

-62%

11%

40%

44%

ROCE

27%

19%

-13%

-49%

16%

62%

55%

Fixed Asset Turnover

6.45

5.49

3.58

2.88

2.91

3.61

4.11

6.05

7.24

4.94

Receivable days

Inventory Days

Payable days

Cash Conversion Cycle

Total Debt/Equity

0.00

Interest Cover

646

Astrazeneca Pharma India Ltd.

Pharmaceuticals & Drugs - Domestic

BSE: 506820 | NSE: ASTRAZEN

Stock Summary

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

EBITDA CAGR (%)

PAT CAGR (%)

P:E (Median)

P:BV (Average)

EV:EBITDA (Average)

Quarterly Results

Standalone Figures in Rs. Crores

Annual Results

Standalone Figures in Rs. Crores

Results Balance Sheet

Standalone Figures in Rs. Crores

Cash Flow

Standalone Figures in Rs. Crores

Financial Ratios

Standalone

Annual Reports:

News Update

Astrazeneca Pharma India Ltd.

Pharmaceuticals & Drugs - Domestic

BSE: 506820 | NSE: ASTRAZEN

Stock Summary

Shareholding Pattern

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

EBITDA CAGR (%)

PAT CAGR (%)

P:E (Median)

P:BV (Average)

EV:EBITDA (Average)

Quarterly Results

Standalone Figures in Rs. Crores

Annual Results

Standalone Figures in Rs. Crores

Results Balance Sheet

Standalone Figures in Rs. Crores

Cash Flow

Standalone Figures in Rs. Crores

Financial Ratios

Standalone

Annual Reports:

News Update